Entero Vu Generic Name: 24% barium sulfate suspension Brand Name: Entero Vu side effects drug center entero vu (24% barium sulfate suspension) drug Related Drugs Cystografin EZ Cat Dry EZ-Disk Gastrografin Liquid E-Z-PAQUE MD-Gastroview Readi-cat 2 Sinografin Tagitol V Varibar Honey Varibar Nectar Varibar Thin Honey Varibar Thin Liquid VoLumen PROFESSIONAL CONSUMER SIDE EFFECTS Contents Drug Description Indications & Dosage Side Effects & Drug Interactions Warnings & Precautions Overdosage & Contraindications Clinical Pharmacology Medication Guide Drug Description What is Entero Vu and how is it used?Entero Vu (24% barium sulfate suspension) is a positive contrast agent for radiographic studies indicated for radiography of the gastrointestinal tract.What are side effects of Entero Vu?Side effects of Entero Vu are uncommon and usually mild and include:nausea,vomiting,diarrhea and abdominal crampingENTERO VU™ 24%(barium sulfate) 24% SuspensionDESCRIPTIONENTERO VU™ 24% Barium Sulfate Suspension (24% w/v, 20% w/w) is a barium sulfate suspension for oral administration. Each 100 mL contains 24 g barium sulfate. Barium sulfate, due to its high molecular density is opaque to x-rays and, therefore, acts as a positive contrast agent for radiographic studies. The active ingredient is barium sulfate and its structural formula is BaSO4. Barium sulfate occurs as a fine, white, odorless, tasteless, bulky powder which is free from grittiness. Its aqueous suspensions are neutral to litmus. It is practically insoluble in water, solutions of acids and alkalies, and organic solvents.Inactive Ingredients : acacia, carrageenan, citric acid, methylcellulose, natural and artificial blueberry flavor, polysorbate 80, potassium chloride, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, sorbitol solution, and xanthan gum. Indications & Dosage INDICATIONSENTERO VU 24% is indicated for use in small bowel radiographic examinations to visualize the gastrointestinal (GI) tract in adult patients. DOSAGE AND ADMINISTRATIONRecommended DosingThe recommended oral dose of ENTERO VU 24% is:Adults: 600 mLAdministration InstructionsFor oral use onlyShake bottle vigorously prior to oral administration to fully suspend productAdminister undilutedDiscard any unused suspensionAdvise patients to hydrate following the barium sulfate procedureAdvise patient at risk for constipation or delayed gastrointestinal transit to monitor for worsening of their condition after administration of barium sulfate and seek medical attention if worsening and advise using laxatives to enhance gastrointestinal transit. HOW SUPPLIEDDosage Forms And StrengthsOral suspension: barium sulfate (24% w/v) supplied in a single-dose white HDPE plastic bottle as a ready-to-use suspension for oral administration. Each bottle contains 600 mL of suspension.ENTERO VU 24% (barium sulfate) is supplied as a suspension (24% w/v) in a single-dose HDPE plastic bottle containing 600 mL of barium sulfate suspension (24% w/v).Provided as: 12 x 600 mL bottles (NDC 32909-145-06)Storage And HandlingStore at USP controlled room temperature 20°C to 25°C (68°F to 77° F). Protect from freezing.Manufactured by: EZEM Canada Inc, Anjou (Quebec) Canada H1J 2Z4. Revised: May 2020 Side Effects & Drug Interactions SIDE EFFECTSThe following adverse reactions have been identified from spontaneous reporting or clinical studies of barium sulfate administered orally. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure:Nausea, vomiting, diarrhea and abdominal crampingSerious adverse reactions and fatalities include aspiration pneumonitis, barium sulfate impaction, intestinal perforation with consequent peritonitis and granuloma formation, vasovagal and syncopal episodes DRUG INTERACTIONSNo Information Provided Overdosage & Contraindications OVERDOSENo Information Provided CONTRAINDICATIONSENTERO VU 24% is contraindicated in patients with the following conditions:known or suspected perforation of the GI tractknown obstruction of the GI tracthigh risk of GI perforation such as those with a recent GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to the pelvishigh risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundationknown severe hypersensitivity to barium sulfate or any of the excipients of ENTERO VU 24% Clinical Pharmacology CLINICAL PHARMACOLOGYMechanism Of ActionDue to its high atomic number, barium (the active ingredient in ENTERO VU 24%) is opaque to x-rays and therefore acts as a positive contrast agent for radiographic studies.PharmacodynamicsBarium sulfate is biologically inert and has no known pharmacological effects.PharmacokineticsUnder physiological conditions, barium sulfate passes through the gastrointestinal tract in an unchanged form and is absorbed only in small, pharmacologically insignificant amounts. Medication Guide PATIENT INFORMATIONAfter administration, advise patients to:Maintain adequate hydration [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].Seek medical attention for worsening of constipation or slow gastrointestinal passage [see WARNINGS AND PRECAUTIONS].Seek medical attention for any delayed onset of hypersensitivity: rash, urticaria, or respiratory difficulty [see WARNINGS AND PRECAUTIONS].
Drug Description What is Entero Vu and how is it used?Entero Vu (24% barium sulfate suspension) is a positive contrast agent for radiographic studies indicated for radiography of the gastrointestinal tract.What are side effects of Entero Vu?Side effects of Entero Vu are uncommon and usually mild and include:nausea,vomiting,diarrhea and abdominal crampingENTERO VU™ 24%(barium sulfate) 24% SuspensionDESCRIPTIONENTERO VU™ 24% Barium Sulfate Suspension (24% w/v, 20% w/w) is a barium sulfate suspension for oral administration. Each 100 mL contains 24 g barium sulfate. Barium sulfate, due to its high molecular density is opaque to x-rays and, therefore, acts as a positive contrast agent for radiographic studies. The active ingredient is barium sulfate and its structural formula is BaSO4. Barium sulfate occurs as a fine, white, odorless, tasteless, bulky powder which is free from grittiness. Its aqueous suspensions are neutral to litmus. It is practically insoluble in water, solutions of acids and alkalies, and organic solvents.Inactive Ingredients : acacia, carrageenan, citric acid, methylcellulose, natural and artificial blueberry flavor, polysorbate 80, potassium chloride, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, sorbitol solution, and xanthan gum. Indications & Dosage INDICATIONSENTERO VU 24% is indicated for use in small bowel radiographic examinations to visualize the gastrointestinal (GI) tract in adult patients. DOSAGE AND ADMINISTRATIONRecommended DosingThe recommended oral dose of ENTERO VU 24% is:Adults: 600 mLAdministration InstructionsFor oral use onlyShake bottle vigorously prior to oral administration to fully suspend productAdminister undilutedDiscard any unused suspensionAdvise patients to hydrate following the barium sulfate procedureAdvise patient at risk for constipation or delayed gastrointestinal transit to monitor for worsening of their condition after administration of barium sulfate and seek medical attention if worsening and advise using laxatives to enhance gastrointestinal transit. HOW SUPPLIEDDosage Forms And StrengthsOral suspension: barium sulfate (24% w/v) supplied in a single-dose white HDPE plastic bottle as a ready-to-use suspension for oral administration. Each bottle contains 600 mL of suspension.ENTERO VU 24% (barium sulfate) is supplied as a suspension (24% w/v) in a single-dose HDPE plastic bottle containing 600 mL of barium sulfate suspension (24% w/v).Provided as: 12 x 600 mL bottles (NDC 32909-145-06)Storage And HandlingStore at USP controlled room temperature 20°C to 25°C (68°F to 77° F). Protect from freezing.Manufactured by: EZEM Canada Inc, Anjou (Quebec) Canada H1J 2Z4. Revised: May 2020 Side Effects & Drug Interactions SIDE EFFECTSThe following adverse reactions have been identified from spontaneous reporting or clinical studies of barium sulfate administered orally. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure:Nausea, vomiting, diarrhea and abdominal crampingSerious adverse reactions and fatalities include aspiration pneumonitis, barium sulfate impaction, intestinal perforation with consequent peritonitis and granuloma formation, vasovagal and syncopal episodes DRUG INTERACTIONSNo Information Provided Overdosage & Contraindications OVERDOSENo Information Provided CONTRAINDICATIONSENTERO VU 24% is contraindicated in patients with the following conditions:known or suspected perforation of the GI tractknown obstruction of the GI tracthigh risk of GI perforation such as those with a recent GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to the pelvishigh risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundationknown severe hypersensitivity to barium sulfate or any of the excipients of ENTERO VU 24% Clinical Pharmacology CLINICAL PHARMACOLOGYMechanism Of ActionDue to its high atomic number, barium (the active ingredient in ENTERO VU 24%) is opaque to x-rays and therefore acts as a positive contrast agent for radiographic studies.PharmacodynamicsBarium sulfate is biologically inert and has no known pharmacological effects.PharmacokineticsUnder physiological conditions, barium sulfate passes through the gastrointestinal tract in an unchanged form and is absorbed only in small, pharmacologically insignificant amounts. Medication Guide PATIENT INFORMATIONAfter administration, advise patients to:Maintain adequate hydration [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].Seek medical attention for worsening of constipation or slow gastrointestinal passage [see WARNINGS AND PRECAUTIONS].Seek medical attention for any delayed onset of hypersensitivity: rash, urticaria, or respiratory difficulty [see WARNINGS AND PRECAUTIONS].
